Research ArticleArticle

Hydroxychloroquine Blood Levels in Systemic Lupus Erythematosus: Clarifying Dosing Controversies and Improving Adherence

Laura Durcan, William A. Clarke, Laurence S. Magder and Michelle Petri
The Journal of Rheumatology November 2015, 42 (11) 2092-2097; DOI: https://doi.org/10.3899/jrheum.150379

REFERENCES

  1. 1.↵
    A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. N Engl J Med 1991;324:150–4.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Wallace DJ
    . Does hydroxychloroquine sulfate prevent clot formation in systemic lupus erythematosus? Arthritis Rheum 1987;30:1435–6.
    OpenUrlPubMed
  3. 3.↵
    1. Ruiz-Irastorza G,
    2. Egurbide MV,
    3. Pijoan JI,
    4. Garmendia M,
    5. Villar I,
    6. Martinez-Berriotxoa A,
    7. et al.
    Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus 2006;15:577–83.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Petri M
    . Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients. Curr Rheumatol Rep 2011;13:77–80.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Espinola RG,
    2. Pierangeli SS,
    3. Gharavi AE,
    4. Harris EN
    . Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies. Thromb Haemost 2002;87:518–22.
    OpenUrlPubMed
  6. 6.↵
    1. Cairoli E,
    2. Rebella M,
    3. Danese N,
    4. Garra V,
    5. Borba EF
    . Hydroxychloroquine reduces low-density lipoprotein cholesterol levels in systemic lupus erythematosus: a longitudinal evaluation of the lipid-lowering effect. Lupus 2012;21:1178–82.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Quatraro A,
    2. Consoli G,
    3. Magno M,
    4. Caretta F,
    5. Nardozza A,
    6. Ceriello A,
    7. et al.
    Hydroxychloroquine in decompensated, treatment-refractory noninsulin-dependent diabetes mellitus. A new job for an old drug? Ann Intern Med 1990;112:678–81.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Gerstein HC,
    2. Thorpe KE,
    3. Taylor DW,
    4. Haynes RB
    . The effectiveness of hydroxychloroquine in patients with type 2 diabetes mellitus who are refractory to sulfonylureas—a randomized trial. Diabetes Res Clin Pract 2002;55:209–19.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Wasko MC,
    2. Hubert HB,
    3. Lingala VB,
    4. Elliott JR,
    5. Luggen ME,
    6. Fries JF,
    7. et al.
    Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. JAMA 2007;298:187–93.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Kuhn A,
    2. Ruland V,
    3. Bonsmann G
    . Cutaneous lupus erythematosus: update of therapeutic options part I. J Am Acad Dermatol 2011;65:e179–93.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Williams HJ,
    2. Egger MJ,
    3. Singer JZ,
    4. Willkens RF,
    5. Kalunian KC,
    6. Clegg DO,
    7. et al.
    Comparison of hydroxychloroquine and placebo in the treatment of the arthropathy of mild systemic lupus erythematosus. J Rheumatol 1994;21:1457–62.
    OpenUrlPubMed
  12. 12.↵
    1. Kasitanon N,
    2. Fine DM,
    3. Haas M,
    4. Magder LS,
    5. Petri M
    . Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis. Lupus 2006;15:366–70.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Alarcón GS,
    2. McGwin G,
    3. Bertoli AM,
    4. Fessler BJ,
    5. Calvo-Alén J,
    6. Bastian HM,
    7. et al;
    8. LUMINA Study Group
    . Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis 2007;66:1168–72.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Fessler BJ,
    2. Alarcón GS,
    3. McGwin G Jr,
    4. Roseman J,
    5. Bastian HM,
    6. Friedman AW,
    7. et al.
    Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum 2005;52:1473–80.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Petri M,
    2. Perez-Gutthann S,
    3. Longenecker JC,
    4. Hochberg M
    . Morbidity of systemic lupus erythematosus: role of race and socioeconomic status. Am J Med 1991;91:345–53.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Uribe AG,
    2. Ho KT,
    3. Agee B,
    4. McGwin G Jr,
    5. Fessler BJ,
    6. Bastian HM,
    7. et al.
    Relationship between adherence to study and clinic visits in systemic lupus erythematosus patients: data from the LUMINA cohort. Lupus 2004;13:561–8.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    1. Mosley-Williams A,
    2. Lumley MA,
    3. Gillis M,
    4. Leisen J,
    5. Guice D
    . Barriers to treatment adherence among African American and white women with systemic lupus erythematosus. Arthritis Rheum 2002;47:630–8.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Oliveira-Santos M,
    2. Verani JF,
    3. Klumb EM,
    4. Albuquerque EM
    . Evaluation of adherence to drug treatment in patients with systemic lupus erythematosus in Brazil. Lupus 2011;20:320–9.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    1. Koneru S,
    2. Shishov M,
    3. Ware A,
    4. Farhey Y,
    5. Mongey AB,
    6. Graham TB,
    7. et al.
    Effectively measuring adherence to medications for systemic lupus erythematosus in a clinical setting. Arthritis Rheum 2007;57:1000–6.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Costedoat-Chalumeau N,
    2. Pouchot J,
    3. Guettrot-Imbert G,
    4. Le Guern V,
    5. Leroux G,
    6. Marra D,
    7. et al.
    Adherence to treatment in systemic lupus erythematosus patients. Best Pract Res Clin Rheumatol 2013;27:329–40.
    OpenUrlCrossRef
  21. 21.↵
    1. Costedoat-Chalumeau N,
    2. Amoura Z,
    3. Hulot JS,
    4. Aymard G,
    5. Leroux G,
    6. Marra D,
    7. et al.
    Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus. Ann Rheum Dis 2007;66:821–4.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    1. Julian LJ,
    2. Yelin E,
    3. Yazdany J,
    4. Panopalis P,
    5. Trupin L,
    6. Criswell LA,
    7. et al.
    Depression, medication adherence, and service utilization in systemic lupus erythematosus. Arthritis Rheum 2009;61:240–6.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Ting TV,
    2. Kudalkar D,
    3. Nelson S,
    4. Cortina S,
    5. Pendl J,
    6. Budhani S,
    7. et al.
    Usefulness of cellular text messaging for improving adherence among adolescents and young adults with systemic lupus erythematosus. J Rheumatol 2012;39:174–9.
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    1. Costedoat-Chalumeau N,
    2. Amoura Z,
    3. Hulot JS,
    4. Hammoud HA,
    5. Aymard G,
    6. Cacoub P,
    7. et al.
    Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum 2006;54:3284–90.
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. Francès C,
    2. Cosnes A,
    3. Duhaut P,
    4. Zahr N,
    5. Soutou B,
    6. Ingen-Housz-Oro S,
    7. et al.
    Low blood concentration of hydroxychloroquine in patients with refractory cutaneous lupus erythematosus: a French multicenter prospective study. Arch Dermatol 2012;148:479–84.
    OpenUrlCrossRefPubMed
  26. 26.↵
    1. Costedoat-Chalumeau N,
    2. Galicier L,
    3. Aumaître O,
    4. Francès C,
    5. Le Guern V,
    6. Lioté F,
    7. et al;
    8. Group PLUS
    . Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study). Ann Rheum Dis 2013;72:1786–92.
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    1. Munster T,
    2. Gibbs JP,
    3. Shen D,
    4. Baethge BA,
    5. Botstein GR,
    6. Caldwell J,
    7. et al.
    Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis. Arthritis Rheum 2002;46:1460–9.
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Petri M,
    2. Purvey S,
    3. Fang H,
    4. Magder LS
    . Predictors of organ damage in systemic lupus erythematosus: the Hopkins Lupus Cohort. Arthritis Rheum 2012;64:4021–8.
    OpenUrlCrossRefPubMed
  29. 29.↵
    1. Füzéry AK,
    2. Breaud AR,
    3. Emezienna N,
    4. Schools S,
    5. Clarke WA
    . A rapid and reliable method for the quantitation of hydroxychloroquine in serum using turbulent flow liquid chromatography-tandem mass spectrometry. Clin Chim Acta 2013;421:79–84.
    OpenUrlCrossRef
  30. 30.↵
    1. Petri M,
    2. Kim MY,
    3. Kalunian KC,
    4. Grossman J,
    5. Hahn BH,
    6. Sammaritano LR,
    7. et al;
    8. OC-SELENA Trial
    . Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005;353:2550–8.
    OpenUrlCrossRefPubMed
  31. 31.↵
    1. Petri M,
    2. Bello KJ,
    3. Fang H,
    4. Magder LS
    . Vitamin D in systemic lupus erythematosus: modest association with disease activity and the urine protein-to-creatinine ratio. Arthritis Rheum 2013;65:1865–71.
    OpenUrlCrossRefPubMed
  32. 32.↵
    1. Haynes RB,
    2. Ackloo E,
    3. Sahota N,
    4. McDonald HP,
    5. Yao X
    . Interventions for enhancing medication adherence. Cochrane Database Syst Rev 2008:CD000011.
  33. 33.↵
    1. Peterson AM,
    2. Takiya L,
    3. Finley R
    . Meta-analysis of trials of interventions to improve medication adherence. Am J Health Syst Pharm 2003;60:657–65.
    OpenUrlAbstract/FREE Full Text
  34. 34.↵
    1. Bruce IN,
    2. Gladman DD,
    3. Urowitz MB
    . Factors associated with refractory renal disease in patients with systemic lupus erythematosus: the role of patient nonadherence. Arthritis Care Res 2000;13:406–8.
    OpenUrlCrossRefPubMed
  35. 35.↵
    1. Chisholm-Burns MA,
    2. Spivey CA,
    3. Graff Zivin J,
    4. Lee JK,
    5. Sredzinski E,
    6. Tolley EA
    . Improving outcomes of renal transplant recipients with behavioral adherence contracts: a randomized controlled trial. Am J Transplant 2013;13:2364–73.
    OpenUrlCrossRefPubMed
  36. 36.↵
    1. Leiva A,
    2. Aguiló A,
    3. Fajó-Pascual M,
    4. Moreno L,
    5. Martín MC,
    6. Garcia EM,
    7. et al.
    Efficacy of a brief multifactorial adherence-based intervention in reducing blood pressure: a randomized clinical trial. Patient Prefer Adherence 2014;8:1683–90.
    OpenUrlPubMed
  37. 37.↵
    1. Moise N,
    2. Schwartz J,
    3. Bring R,
    4. Shimbo D,
    5. Kronish IM
    . Antihypertensive drug class and adherence: an electronic monitoring study. Am J Hypertens 2015;28:717–21.
    OpenUrlAbstract/FREE Full Text
  38. 38.↵
    1. Ogedegbe G,
    2. Tobin JN,
    3. Fernandez S,
    4. Cassells A,
    5. Diaz-Gloster M,
    6. Khalida C,
    7. et al.
    Counseling African Americans to Control Hypertension: cluster-randomized clinical trial main effects. Circulation 2014;129:2044–51.
    OpenUrlAbstract/FREE Full Text
  39. 39.↵
    1. Thom DH,
    2. Willard-Grace R,
    3. Hessler D,
    4. DeVore D,
    5. Prado C,
    6. Bodenheimer T,
    7. et al.
    The impact of health coaching on medication adherence in patients with poorly controlled diabetes, hypertension, and/or hyperlipidemia: a randomized controlled trial. J Am Board Fam Med 2015;28:38–45.
    OpenUrlAbstract/FREE Full Text
  40. 40.↵
    1. Aikens JE,
    2. Trivedi R,
    3. Aron DC,
    4. Piette JD
    . Integrating Support Persons into Diabetes Telemonitoring to Improve Self-Management and Medication Adherence. J Gen Intern Med 2015;30:319–26.
    OpenUrlCrossRefPubMed
  41. 41.↵
    1. Low JK,
    2. Williams A,
    3. Manias E,
    4. Crawford K
    . Interventions to improve medication adherence in adult kidney transplant recipients: a systematic review. Nephrol Dial Transplant 2015;30:752–61.
    OpenUrlAbstract/FREE Full Text
  42. 42.↵
    1. Huisman AM,
    2. White KP,
    3. Algra A,
    4. Harth M,
    5. Vieth R,
    6. Jacobs JW,
    7. et al.
    Vitamin D levels in women with systemic lupus erythematosus and fibromyalgia. J Rheumatol 2001;28:2535–9.
    OpenUrlAbstract/FREE Full Text
  43. 43.↵
    1. Angelakis E,
    2. Oddoze C,
    3. Raoult D
    . Vitamin D and prolonged treatment with photosensitivity-associated antibiotics. Antimicrob Agents Chemother 2013;57:6409–10.
    OpenUrlFREE Full Text
  44. 44.↵
    1. Schoindre Y,
    2. Jallouli M,
    3. Tanguy ML,
    4. Ghillani P,
    5. Galicier L,
    6. Aumaître O,
    7. et al.
    Lower vitamin D levels are associated with higher systemic lupus erythematosus activity, but not predictive of disease flare-up. Lupus Sci Med 2014;1:e000027.
    OpenUrlAbstract/FREE Full Text
  45. 45.↵
    1. Petri MA,
    2. van Vollenhoven RF,
    3. Buyon J,
    4. Levy RA,
    5. Navarra SV,
    6. Cervera R,
    7. et al;
    8. BLISS-52 and BLISS-76 Study Groups
    . Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials. Arthritis Rheum 2013;65:2143–53.
    OpenUrlCrossRefPubMed
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

 Request Permissions

Bookmark this article

Jump to section

Keywords

HYDROXYCHLOROQUINE
SLE
DISEASE ACTIVITY
ADHERENCE

Keywords